Literature DB >> 7744521

Removal of antiacetylcholine receptor antibodies by protein-A immunoadsorption in myasthenia gravis.

E Berta1, P Confalonieri, O Simoncini, G Bernardi, G Busnach, R Mantegazza, F Cornelio, C Antozzi.   

Abstract

Myasthenia Gravis is an autoimmune disease in which autoantibodies to the acetylcholine receptor interfere with neuromuscular transmission. Plasma exchange is effective in temporarily relieving the symptoms of the disease, but for repeated use the lack of selectivity and need for replacement fluids (which increases the risk of contracting viral diseases) are important drawbacks. Staphylococcal protein A, a potent ligand for immunoglobulins, that interacts negligibly with other plasma proteins, appears to be an optimal candidate for removing antiacetylcholine receptor antibodies, which are mostly IgG. We treated three patients with severe immunosuppression-resistant myasthenia gravis with protein A immunoadsorption. Neurological impairment significantly improved in all patients. After immunoadsorption of 1.5-2 plasma volumes per session, the mean percentage reductions for serum IgG and specific autoantibodies were 71% and 82% respectively. No major side effects occurred. Protein A immunoadsorption appears to be a safe, efficient and effective alternative to plasmaexchange for selected myasthenic patients requiring prolonged apheresis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7744521

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  4 in total

1.  Treatment of passively transferred experimental autoimmune myasthenia gravis using papain.

Authors:  K Poulas; T Tsouloufis; S J Tzartos
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

Review 2.  Role of autoantibodies in the physiopathology of Chagas' disease.

Authors:  Emiliano Horacio Medei; José Hamilton Matheus Nascimento; Roberto Coury Pedrosa; Antônio Carlos Campos de Carvalho
Journal:  Arq Bras Cardiol       Date:  2008-10       Impact factor: 2.000

Review 3.  The acetylcholine receptor ligand-gated channel as a molecular target of disease and therapeutic agents.

Authors:  F J Barrantes
Journal:  Neurochem Res       Date:  1997-04       Impact factor: 3.996

4.  IdeS: a bacterial proteolytic enzyme with therapeutic potential.

Authors:  Björn P Johansson; Oonagh Shannon; Lars Björck
Journal:  PLoS One       Date:  2008-02-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.